State Street
MAZE

State Street’s Maze Therapeutics MAZE Stock Holding History

State Street’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.8M Buy
997,533
+360,811
+57% +$9.46M ﹤0.01% 2160
2026
Q1 		$19M Buy
636,722
+103,717
+19% +$4.58M ﹤0.01% 2265
2025
Q4 		$22.1M Buy
533,005
+148,303
+39% +$5.1M ﹤0.01% 2210
2025
Q3 		$9.98M Buy
384,702
+240,017
+166% +$4.05M ﹤0.01% 2644
2025
Q2 		$1.78M Buy
144,685
+79,972
+124% +$832K ﹤0.01% 3350
2025
Q1 		$712K Buy
+64,713
New +$779K ﹤0.01% 3513

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

State Street's MAZE Position: Q2 2026 in Review

State Street increased its Maze Therapeutics (MAZE) stake by 57% in Q2 2026, buying an estimated $9.46M and bringing the position to 997,533 shares worth $29.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2160.

State Street first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. 161 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • State Street held 997,533 shares of Maze Therapeutics worth $29.8M as of Q2 2026.
  • State Street bought 360,811 Maze Therapeutics shares in Q2 2026, an estimated $9.46M.
  • Maze Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2160 holding.
  • State Street first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 161 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.